Immunocore Holdings' stock has dropped 60% as Kimmtrak faces market saturation, but its pipeline could offer potential. Find ...

Gilead Sciences' Q1 2025 earnings reveal challenges in oncology and Veklury sales, while HIV therapies remain strong. See why ...